146013-28-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Thiophenesulfonamide, N-(1,1-dimethylethyl)-5-(2-methylpropyl)-, is used as a potential antibiotic for the treatment of bacterial infections. Its sulfonamide structure allows it to inhibit bacterial growth by interfering with folic acid synthesis, which is essential for the survival and reproduction of bacteria.
2-Thiophenesulfonamide, N-(1,1-dimethylethyl)-5-(2-methylpropyl)-, is also used as a potential diuretic for the treatment of hypertension and other conditions that require increased urine production. Its ability to promote the excretion of water and electrolytes can help lower blood pressure and reduce fluid retention in the body.
Further research and testing are necessary to determine the specific uses, efficacy, and safety of 2-Thiophenesulfonamide, N-(1,1-dimethylethyl)-5-(2-methylpropyl)-, in various medical applications. Its unique chemical structure and pharmacological properties hold promise for the development of novel therapeutic agents.

Upstream product

• 513-38-2 Isobutyl iodide 
• 100342-30-1 thiophene-2-sulfonic acid tert-butylamide 
• 89124-64-1 iodo-2-methylpropane 
• 78-77-3 Isobutyl bromide 
• 5674-02-2 2-methylpropylmagnesium chloride 
• 286932-39-6 5-bromothiophene-2-sulphonic acid tert-butylamide 

Downstream Products

• 477775-35-2 3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-N-tert-butylthiophene-2-sulfonamide 
• 477775-36-3 3-[4-[(1H-imidazol-1-yl)methyl]phenyl]-5-isobutylthiophene-2-sulfonamide 
• 477775-14-7 MO 24 
• 912962-74-4 3-(3-((1H-imidazol-1-yl)methyl)phenyl)-N-(tert-butyl)-5-isobutylthiophene-2-sulfonamide 

Relevant academic research and scientific papers

Synthesis of 11C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C]CO

We describe the development of a new methodology focusing on 11C-labeling of sulfonyl carbamates in a multicomponent reaction comprised of a sulfonyl azide, an alkyl alcohol, and [11C]CO. A number of 11C-labeled sulfonyl carbamates were synthesized and isolated, and the developed methodology was then applied in the preparation of a biologically active molecule. The target compound was obtained in 24±10 % isolated radiochemical yield and was evaluated for binding properties in a tumor cell assay; in vivo biodistribution and imaging studies were also performed. This represents the first successful radiolabeling of a non-peptide angiotensin II receptor subtype 2 agonist, C21, currently in clinical trials for the treatment of idiopathic pulmonary fibrosis.

Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity

Mutating the side-chains of amino acids in a peptide ligand, with unnatural amino acids, aiming to mitigate its short half-life is an established approach. However, it is hypothesized that mutating specific backbone peptide bonds with bioisosters can be exploited not only to enhance the proteolytic stability of parent peptides, but also to tune its receptor subtype selectivity. Towards this end, four [Y]6-Angiotensin II analogues are synthesized where amide bonds have been replaced by 1,4-disubstituted 1,2,3-triazole isosteres in four different backbone locations. All the analogues possessed enhanced stability in human plasma in comparison with the parent peptide, whereas only two of them achieved enhanced AT2R/AT1R subtype selectivity. This diversification has been studied through 2D NMR spectroscopy and unveiled a putative more structured microenvironment for the two selective ligands accompanied with increased number of NOE cross-peaks. The most potent analogue, compound 2, has been explored regarding its neurotrophic potential and resulted in an enhanced neurite growth with respect to the established agent C21.

A Series of Analogues to the AT2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode

We here report on our continued studies of ligands binding to the promising drug target angiotensin II type 2 receptor (AT2R). Two series of compounds were synthesized and investigated. The first series explored the effects of adding small subs

A convenient transesterification method for synthesis of AT2 receptor ligands with improved stability in human liver microsomes

A series of AT2R ligands have been synthesized applying a quick, simple, and safe transesterification-type reaction whereby the sulfonyl carbamate alkyl tail of the selective AT2R antagonist C38 was varied. Furthermore, a limited number of compounds where acyl sulfonamides and sulfonyl ureas served as carboxylic acid bioisosteres were synthesized and evaluated. By reducing the size of the alkyl chain of the sulfonyl carbamates, ligands 7a and 7b were identified with significantly improved in vitro metabolic stability in both human and mouse liver microsomes as compared to C38 while retaining the AT2R binding affinity and AT2R/AT1R selectivity. Eight of the compounds synthesized exhibit an improved stability in human microsomes as compared to C38.

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I) wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings giv

NEW BICYCLIC ANGIOTENSIN II AGONISTS

There is provided a compound of formula (I) wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and ph

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of Formula (I), wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceuticalfy-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein the dotted lines, XI, X2, X3, X4, A, YI, Y2, Y3, Y4, ZI, Z2, R2 and R3

NEW BICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein R1a, R1b, n, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

NEW TRICYCLIC ANGIOTENSIN II AGONISTS

There is provided compounds of formula (I), wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings gi